Influenzinum

Influenza A Virus is utilized as a non-standardized allergenic extract for diagnostic skin testing and immunotherapy. It belongs to the class of allergenic extracts used to identify or treat specific hypersensitivity reactions in patients.

Dosage for Influenza A Virus allergenic extract is highly individualized and must be determined by an allergy specialist (allergist or immunologist). There is no 'standard' dose due to the non-standardized nature of the product.

• Diagnostic Skin Prick Test: Typically, one drop of the extract (e.g., 1:10 or 1:20 w/v) is applied to the skin, followed by a prick or scratch. A positive control (histamine) and a negative control (saline) are used for comparison.
• Intradermal Testing: If the prick test is negative, a dose of 0.02 mL to 0.05 mL of a highly diluted extract (e.g., 1:1000 w/v) may be injected into the dermis.
• Immunotherapy: Dosing begins at a very low concentration (the 'build-up phase') and increases weekly or bi-weekly until a maintenance dose is reached. The maintenance dose is the highest dose the patient can tolerate without a significant local or systemic reaction.

Influenza A Virus allergenic extract can be used in children, but the procedure requires extreme caution. Pediatric dosing is generally similar to adult dosing in terms of the concentration used for skin testing, but the volume and number of tests performed in one session may be reduced to minimize discomfort and the risk of systemic reactions. Your pediatrician or pediatric allergist will determine the appropriate protocol based on the child's age, weight, and clinical history. It is generally not recommended for infants unless specifically indicated by a specialist.

Renal Impairment

No specific dosage adjustments are required for patients with kidney disease, as the systemic absorption of the extract is minimal. However, the patient's overall health and ability to tolerate a potential systemic reaction should be considered.

Hepatic Impairment

No dosage adjustments are necessary for patients with liver impairment. The metabolic pathway of protein degradation is not significantly affected by liver enzyme capacity in the context of allergenic testing.

Elderly Patients

Older adults may have reduced skin reactivity (delayed or smaller wheal response), which can lead to false-negative results. Additionally, elderly patients often have underlying cardiovascular conditions that increase the risk of complications if a systemic allergic reaction occurs. Healthcare providers may use lower starting doses for immunotherapy in this population.

Influenza A Virus allergenic extract is never self-administered by the patient. It is always administered by a healthcare professional in a clinical setting.

• Preparation: The skin (usually the forearm or back) is cleaned with alcohol.
• Administration: For testing, the skin is pricked or injected. For immunotherapy, the extract is injected subcutaneously (under the skin) in the upper arm.
• Observation: Patients MUST remain in the medical office for at least 30 minutes after any injection or skin test to be monitored for signs of anaphylaxis.
• Storage: The extract must be kept refrigerated at 2°C to 8°C (36°F to 46°F). It should never be frozen, as this can denature the proteins and render the extract ineffective or dangerous.

In the context of immunotherapy, consistency is vital. If a maintenance or build-up dose is missed, your doctor may need to reduce the dose for the next injection, depending on how much time has passed. Missing multiple doses may require restarting the build-up phase from a lower concentration to ensure safety.

An 'overdose' in the context of allergenic extracts refers to the administration of too much antigen, leading to a severe systemic reaction.

• Signs: Hives (urticaria), swelling of the throat (angioedema), wheezing, difficulty breathing, rapid pulse, and a sharp drop in blood pressure.
• Emergency Measures: Immediate administration of epinephrine (adrenaline), followed by antihistamines, corticosteroids, and emergency transport to a hospital.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not attempt to alter the schedule of your immunotherapy without medical guidance.

Most patients undergoing testing or treatment with Influenza A Virus allergenic extract will experience localized reactions at the site of administration. These are generally not dangerous but can be uncomfortable.

• Local Wheal and Flare: A raised, itchy bump (wheal) surrounded by redness (flare). This typically appears within 15-20 minutes and resolves within a few hours.
• Itching (Pruritus): Intense itching at the test site is a normal part of a positive reaction.
• Local Swelling: For immunotherapy injections, swelling up to the size of a half-dollar is common and may last for 24 to 48 hours.

Influenza A Virus allergenic extract is a potent biological product. It is intended only for use by physicians who are experienced in the administration of allergenic extracts and the treatment of allergic diseases. Because of the risk of systemic reactions, patients must be observed for at least 30 minutes following administration. If you have a history of severe asthma or previous severe reactions to viral antigens, you must inform your doctor, as these factors significantly increase your risk profile.

No specific individual black box warning exists for Influenza A Virus alone, but it falls under the mandatory class-wide black box warning for allergenic extracts. This warning emphasizes that these products can cause anaphylaxis and must be administered in a setting equipped with emergency resuscitative equipment, including oxygen, IV fluids, and epinephrine. The warning also notes that patients with severe or unstable asthma are at increased risk of fatal reactions.

There are few absolute contraindications for drug combinations, but the following are critical:

• Beta-Blockers (e.g., Propranolol, Atenolol): These are often considered a contraindication for allergenic extracts. If you experience anaphylaxis, beta-blockers can block the life-saving effects of epinephrine (adrenaline), making the reaction much harder to treat and potentially fatal.

• ACE Inhibitors (e.g., Lisinopril): Some studies suggest that patients on ACE inhibitors may be at a higher risk for more severe systemic reactions to allergenic extracts.
• MAO Inhibitors (e.g., Phenelzine): These can interfere with the body's ability to process certain stress hormones, potentially complicating the treatment of an allergic reaction.

Influenza A Virus allergenic extract must NEVER be used in the following situations:

1. 1Severe, Unstable Asthma: If your asthma is not well-controlled (e.g., frequent nighttime symptoms or low peak flow), the risk of a fatal respiratory reaction to the extract is too high. The mechanism involves the potential for the extract to trigger a systemic release of mediators that cause immediate, severe bronchospasm.
2. 2Recent Myocardial Infarction (Heart Attack): Within the last 3-6 months. The physiological stress of an allergic reaction or the administration of epinephrine could cause further heart damage.
3. 3Known Hypersensitivity to Extract Components: If you have had a previous life-threatening reaction to this specific extract or any of its inactive ingredients (such as phenol, which is used as a preservative).

Influenza A Virus allergenic extract is generally classified as Pregnancy Category C. This means that adequate and well-controlled studies in pregnant women have not been conducted. The primary concern is not that the extract itself is a teratogen (causes birth defects), but rather the risk of anaphylaxis. If a pregnant woman experiences a severe allergic reaction, her blood pressure may drop, leading to decreased blood flow to the placenta and fetal distress or death. Most allergists will not start new immunotherapy during pregnancy but may continue a maintenance dose if the patient is stable and the benefit outweighs the risk.

It is not known whether the components of Influenza A Virus allergenic extract are excreted in human milk. However, because the antigens are proteins and are administered in very small quantities, it is highly unlikely that they would be absorbed intact from the infant's gut. The risk to a nursing infant is considered very low. Breastfeeding mothers should still inform their doctors before receiving treatment.

Allergenic extracts are used in children, but the safety and efficacy depend on the child's ability to cooperate with the testing and the observation period. Children are at the same risk for anaphylaxis as adults. Special care is taken to ensure the child does not have an underlying respiratory infection at the time of the injection, as this can increase the risk of a reaction. There is no evidence that these extracts affect growth or development.

Influenza A Virus allergenic extract acts as an exogenous antigen. In the diagnostic phase, it interacts with membrane-bound IgE on the surface of mast cells and basophils. This interaction causes the cross-linking of the high-affinity IgE receptor (FcεRI), triggering a signaling cascade that involves tyrosine kinases and an influx of calcium ions. This leads to the immediate release of pre-formed mediators (histamine, tryptase) and the synthesis of lipid mediators. In the therapeutic phase (immunotherapy), the mechanism shifts toward inducing immune tolerance. This involves the expansion of regulatory T-cells (Tregs) that produce IL-10 and TGF-β, which suppress Th2 responses and promote the production of IgG4 antibodies. These IgG4 antibodies act as 'decoy' receptors, binding the viral antigens before they can reach the IgE on mast cells.

• Onset of Action: For skin testing, the onset is rapid (15-20 minutes). For immunotherapy, the clinical benefit (reduction in symptoms) may take 6 to 12 months of consistent treatment.
• Duration of Effect: A positive skin test reaction usually fades within 2 to 4 hours. The effects of successful immunotherapy can last for several years after the treatment is discontinued.